Lee’s Pharma and Partners Plan Global Phase III trial of Cancer Immunotherapy

Lee’s Pharma of Hong Kong, together with partners Transgene SA and SillaJen, plans to start a global Phase III trial of Pexa-Vec, an immunotherapy for cancer, as a first-line treatment for liver cancer during mid-2015. Because Pexa-Vec did not meet its endpoints in a recent Phase II trial, the drug’s future was in doubt. Lee’s owns China rights to Pexa-Vec. Transgene, a listed subsidiary of France’s Institute Merieux, has rights in Europe and the Middle East. SillaJen, a South Korean CRO, recently paid $150 million to acquire Jennerex, which developed Pexa-Vec. More details.... Stock Symbols: (HK: 0950) (PA: TNG) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.